After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying off any staff “not deemed necessary to pursue strategic alternatives.” The ...

Carisma Therapeutics had already laid off 95% of its team earlier this year. Now, a Hail Mary merger proposal with another biotech has fallen through. The cell therapy macrophage biotech had just six ...

PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan ...

During hip-hop's golden era, DJs played a pivotal role in fueling the culture. As the preeminent voices of authority, breaking songs and introducing acts to the mainstream, being a DJ demanded far ...

PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Baird has downgraded Carisma Therapeutics (NASDAQ:CARM) to neutral from outperform, citing a lack of near-term catalysts. The investment firm noted that Carisma (NASDAQ:CARM) has decided to pivot from ...

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Carisma Therapeutics ...

Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will be ...

Carisma Therapeutics and Ocugen's subsidiary OrthoCellix have agreed to a reverse merger to create a new regenerative cell therapies subsidiary. The two companies said Monday in a joint statement that ...